Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J Strosberg, G El-Haddad, E Wolin… - … England Journal of …, 2017 - Mass Medical Soc
Background Patients with advanced midgut neuroendocrine tumors who have had disease
progression during first-line somatostatin analogue therapy have limited therapeutic options …
progression during first-line somatostatin analogue therapy have limited therapeutic options …
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.
J Strosberg, G El-Haddad, E Wolin… - The New England …, 2017 - europepmc.org
Background Patients with advanced midgut neuroendocrine tumors who have had disease
progression during first-line somatostatin analogue therapy have limited therapeutic options …
progression during first-line somatostatin analogue therapy have limited therapeutic options …
Phase 3 trial of 177lu-dotatate for midgut neuroendocrine tumors
J Strosberg, G El-Haddad, E Wolin… - New England …, 2017 - mayoclinic.elsevierpure.com
BACKGROUND Patients with advanced midgut neuroendocrine tumors who have had
disease progression during first-line somatostatin analogue therapy have limited therapeutic …
disease progression during first-line somatostatin analogue therapy have limited therapeutic …
Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors.
J Strosberg, G El-Haddad, E Wolin, A Hendifar, J Yao… - 2017 - mediatum.ub.tum.de
Patients with advanced midgut neuroendocrine tumors who have had disease progression
during first-line somatostatin analogue therapy have limited therapeutic options. This …
during first-line somatostatin analogue therapy have limited therapeutic options. This …
Phase 3 trial of 177lu-dotatate for midgut neuroendocrine tumors
J Strosberg, G El-Haddad… - New England …, 2017 - mdanderson.elsevierpure.com
BACKGROUND Patients with advanced midgut neuroendocrine tumors who have had
disease progression during first-line somatostatin analogue therapy have limited therapeutic …
disease progression during first-line somatostatin analogue therapy have limited therapeutic …
Phase 3 Trial of Lu-177-Dotatate for Midgut Neuroendocrine Tumors
J Strosberg, G El-Haddad, E Wolin… - The New England …, 2017 - iro.uiowa.edu
BACKGROUND Patients with advanced midgut neuroendocrine tumors who have had
disease progression during first-line somatostatin analogue therapy have limited therapeutic …
disease progression during first-line somatostatin analogue therapy have limited therapeutic …
Phase 3 Trial of (177) Lu-Dotatate for Midgut Neuroendocrine Tumors
J Strosberg, G El-Haddad, E Wolin… - New England Journal …, 2017 - kclpure.kcl.ac.uk
Background: Patients with advanced midgut neuroendocrine tumors who have had disease
progression during first-line somatostatin analogue therapy have limited therapeutic options …
progression during first-line somatostatin analogue therapy have limited therapeutic options …
[引用][C] Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J Strosberg, G El-Haddad, E Wolin, A Hendifar… - New England Journal …, 2017 - cir.nii.ac.jp
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J Strosberg, G El Haddad, E Wolin… - NEW ENGLAND …, 2017 - iris.uniroma1.it
Background Patients with advanced midgut neuroendocrine tumors who have had disease
progression during first-line somatostatin analogue therapy have limited therapeutic options …
progression during first-line somatostatin analogue therapy have limited therapeutic options …
Phase 3 trial of 177lu-dotatate for midgut neuroendocrine tumors
J Strosberg, G El-Haddad, E Wolin… - … England Journal of …, 2017 - einstein.elsevierpure.com
BACKGROUND Patients with advanced midgut neuroendocrine tumors who have had
disease progression during first-line somatostatin analogue therapy have limited therapeutic …
disease progression during first-line somatostatin analogue therapy have limited therapeutic …